Treatment of Rheumatoid Arthritis with Methotrexate Alone or A Combination of Methotrexate and Hydroxychloroquine

Natharubini Nadarajah, Riardi Pramudyo, Kuswinarti Kuswinarti

Abstract


Background: Rheumatoid arthritis (RA) is an autoimmune disease that causes significant morbidity in most patients and also premature mortality in some. To prevent this, therapeutic approaches call for the early treatment of RA by using disease-modifying antirheumatic drugs (DMARDSs), either as single therapy or combination therapy. Although in the previous decade DMARDs were rarely used as combination, however now they are used widely to treat RA. The objective of this study was to compare the effectiveness of methotrexate (MTX) alone and the combination of MTX & hydroxychloroquine (HCQ) in RA patients.

Methods: An analytic retrospective cohort study was conducted from May 2014 until October 2014, on 46 patients with RA in the rheumatology clinic of Dr. Hasan Sadikin General Hospital Bandung from January 2009−October 2014 who were taking MTX or MTX & HCQ for at least 1 year. The secondary data obtained from these patients’ medical record were then analyzed using the independent t-test and Mann-Whitney test.

Results: The study showed that 93.48% of the patients were females. The mean change in disease activity measures were not significant for any of the parameter (p-value for SJC = 0.337; TJC = 0.676; ESR = 0.780). Also the comparisons of the disease activity score (DAS 28) before and after therapy was not significant (p-value = 0.584).

Conclusion: There is no difference in the effectiveness of DMARD monotherapy with MTX and combination therapy with MTX & HCQ in RA patients.

DOI: 10.15850/amj.v3n3.474


Keywords


DAS 28, DMARDs, hydroxychloroquine; methotrexate; rheumatoid arthritis

Full Text:

PDF

References


Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, III COB, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(10):1580−8.

Shah A, Clair EWS. Rheumatoid Arthritis. In: Longo DL, Kasper DL,

Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. HARRISON'S Principles of Internal Medicine. 18th ed. New York: McGraw-Hill Companies, Inc.; 2010. p. 2738−2752.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205−19.

Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148(2):124−34.

O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med.

;350(25):2591−602.

Emery P. Treatment of rheumatoid arthritis. Br Med J. 2006;332:152−5.

Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol

Rep. 2006;58:473−92

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados

M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013:1−18.

Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology. 2004;43(12):1504−07

Siegel J. Comparative effectiveness of treatments for rheumatoid arthritis.

Ann Intern Med. 2008;148(2):162−3.

Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004;63:627−33

Smolen J, Keystone EC. Future of RA: building on what we know and

tailoring treatment; biologic therapies beyond conventional DMARDs. Rheumatology. 2012;51:v55−v56

Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68(7):1105−12.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K,

Vollenhoven Rv, et al. The PREMIER study; a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26−37.

O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al.

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two year, randomized, double blind, placebocontrolled trial. Arthritis Rheum. 2002;46(5):1164−70.

Alam MK, Sutradhar SR, Pandit H, Ahmed S, Bhattacharjee M, Miah A,

et al. Comparative study on methotrexate and hydroxychloroquine in the

treatment of rheumatoid arthritis. Mymensingh Med J. 2012;21(3):391−8.

O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287−91.

P H de Jong, Hazes JM, Barendregt PJ, Huisman M, D van Zeben, P A van der Lubbe, et al. Induction therapy with a combination of DMARDs is

better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72−78

Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting

response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43(1):22−9.

Radovits BJ, Fransen J, Van Riel PLCM, Laan RFJM. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis. 2008;67(8):1127−31






 This Journal indexed by:

     

 

Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats